Claymore Kills First, Pharm.D. (He/Him)
- Research Assistant Professor of Division of Oncological Sciences, School of Medicine
Biography
Claymore Kills First, Pharm.D., is an enrolled member of the Oglala Sioux Tribe and Mnicoujou Lakota. Dr. Kills First is a Research Assistant Professor in the Division of Oncological Sciences and board certified oncology pharmacist. His research focuses on identifying and addressing disparities in cancer care for Indigenous populations, including identifying genomic and familial components that increase cancer risk. His projects are built on true collaboration with tribal communities and governments with a focus on equitable research that upholds tribal data sovereignty. This collaboration promotes tribal member input in research design and utilizes community and cultural resources to increase access to healthcare.
Education and training
-
Degrees
- Pharm.D., 2014, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
- B.S., 2009, Walla Walla University
Publications
Selected publications
- Kills First CC, Sutton TL, Shannon J, Brody JR, Sheppard BC. Disparities in pancreatic cancer care and research in Native Americans: Righting a history of wrongs. Cancer. 2022 Apr 15;128(8):1560-1567. doi: 10.1002/cncr.34118. Epub 2022 Feb 8. PubMed PMID: 35132620; PubMed Central PMCID: PMC10257521. https://pubmed.ncbi.nlm.nih.gov/35132620/
- Sutton TL, Kills First CC, Sheppard BC. Overcoming Disparities in Surgical Care among Native Americans. Bulletin of the American College of Surgeons. 2022 April; 107(4). https://bulletin.facs.org/2022/04/overcoming-disparities-in-surgical-care-among-native-americans/ 
- Corsino L, Chigbu JN, Kills First CC, DeWitty VP, Grant-Mills D. Building Your Social Capital Through Mentorship. In: Sanchez J, Brutus NN, editors. Health Professions and Academia Cham, Switzerland: Springer; 2022. Chapter 6; p.67-77. https://link.springer.com/chapter/10.1007/978-3-030-94223-6_6
- Kills First C, Hoyle J, Leong S, Meguid C, Lieu C. A Retrospective Review Of The Impact Of Dose Reductions And Treatment Interruptions Of Neoadjuvant Chemotherapy On Outcomes For Borderline Resectable-Locally Advanced Pancreatic Adenocarcinoma. HOPA Annual Conference. 2018 March; Denver, CO, USA.